🎯First-in-class
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
FDA approves Tryngolza (olezarsen)
FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov
December 20, 2024 at 12:35 AM
🎯First-in-class
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
US FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).
www.fda.gov/drugs/news-e...
Dr. Sam Tsimikas presenting work on olezarsen and Lp(a)-TG #ACC25 #CardioSky @ucsdcardiology.bsky.social
March 30, 2025 at 7:20 PM
Dr. Sam Tsimikas presenting work on olezarsen and Lp(a)-TG #ACC25 #CardioSky @ucsdcardiology.bsky.social
In the phase 3 CORE-TIMI 72a and CORE2-TIMI 72b trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results and Research Summary: nej.md/491XG5V
#MedSky
#MedSky
February 1, 2026 at 8:00 PM
In the phase 3 CORE-TIMI 72a and CORE2-TIMI 72b trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results and Research Summary: nej.md/491XG5V
#MedSky
#MedSky
FDA approves Ionis’ antisense oligonucleotide olezarsen, making it the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down triglycerides.
FDA approves Ionis’ treatment for a rare metabolic disorder
FDA approves Ionis' olezarsen as first treatment for familial chylomicronemia syndrome. Arrowhead's plozasiran pending FDA review. Both target broader SHTG market.
endpts.com
December 20, 2024 at 3:51 PM
FDA approves Ionis’ antisense oligonucleotide olezarsen, making it the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down triglycerides.
LDL-cholesterol is in the causal chain for atherosclerosis. It looks like there is residual risk that LDL-c doesn't explain, and other lipid entities are appealing candidates.
Enter olezarsen, which degrades APOC3 mRNA and reduces ApoC-III levels. This lowers TG & remnant cholesterol.
Enter olezarsen, which degrades APOC3 mRNA and reduces ApoC-III levels. This lowers TG & remnant cholesterol.
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk | NEJM
Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis.
The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein
C-III messenger R...
www.nejm.org
April 1, 2026 at 7:14 PM
LDL-cholesterol is in the causal chain for atherosclerosis. It looks like there is residual risk that LDL-c doesn't explain, and other lipid entities are appealing candidates.
Enter olezarsen, which degrades APOC3 mRNA and reduces ApoC-III levels. This lowers TG & remnant cholesterol.
Enter olezarsen, which degrades APOC3 mRNA and reduces ApoC-III levels. This lowers TG & remnant cholesterol.
New in the October 2, 2025, issue of NEJM:
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
October 2, 2025 at 1:03 PM
New in the October 2, 2025, issue of NEJM:
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
September 29, 2026 at 7:09 PM
It's Trivia Tuesday! This question is from our article Olezarsen (Tryngolza) for Severe Hypertriglyceridemia https://bit.ly/4xOEqBl
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Answer: d
Increases in fasting glucose levels and A1C have also been reported; these were most pronounced in patients with preexisting diabetes.
Importantly, olezarsen barely reduced ApoB and did not reduce LDL-c.
April 1, 2026 at 7:14 PM
Importantly, olezarsen barely reduced ApoB and did not reduce LDL-c.
In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
November 8, 2025 at 2:45 PM
In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
Big news in lipidology!🎉 The FDA has approved TRYNGOLZA™ (olezarsen) 80mg injection — the 1st treatment for adults with familial chylomicronemia syndrome (FCS) to lower triglycerides, alongside diet.
Read the press release: ir.ionis.com/news-release... #LipidScience
Read the press release: ir.ionis.com/news-release... #LipidScience
ir.ionis.com
December 20, 2024 at 4:42 PM
Big news in lipidology!🎉 The FDA has approved TRYNGOLZA™ (olezarsen) 80mg injection — the 1st treatment for adults with familial chylomicronemia syndrome (FCS) to lower triglycerides, alongside diet.
Read the press release: ir.ionis.com/news-release... #LipidScience
Read the press release: ir.ionis.com/news-release... #LipidScience
Big week in #metabolism-related therapies:
Olezarsen (ASO targeting ApoCIII) for familial chylomicronemia:
ir.ionis.com/news-release...
FDA approves tirzepatide for OSA in pts w obesity:
www.fda.gov/news-events/...
CAGRISEMA (amylin analog +GLP1RA) disappoints www.novonordisk.com/news-and-med...
Olezarsen (ASO targeting ApoCIII) for familial chylomicronemia:
ir.ionis.com/news-release...
FDA approves tirzepatide for OSA in pts w obesity:
www.fda.gov/news-events/...
CAGRISEMA (amylin analog +GLP1RA) disappoints www.novonordisk.com/news-and-med...
December 21, 2024 at 10:40 PM
Big week in #metabolism-related therapies:
Olezarsen (ASO targeting ApoCIII) for familial chylomicronemia:
ir.ionis.com/news-release...
FDA approves tirzepatide for OSA in pts w obesity:
www.fda.gov/news-events/...
CAGRISEMA (amylin analog +GLP1RA) disappoints www.novonordisk.com/news-and-med...
Olezarsen (ASO targeting ApoCIII) for familial chylomicronemia:
ir.ionis.com/news-release...
FDA approves tirzepatide for OSA in pts w obesity:
www.fda.gov/news-events/...
CAGRISEMA (amylin analog +GLP1RA) disappoints www.novonordisk.com/news-and-med...
Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume?
Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
March 30, 2026 at 2:22 PM
Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume?
Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
CORE-TIMI 72a and CORE2-TIMI 72b trials: Patients with severe hypertriglyceridemia have an increased risk of pancreatitis despite the use of lipid-lowering therapy. Research findings on the safety and efficacy of olezarsen in this population are summarized in a new video. nej.md/4bkpa7S
January 30, 2026 at 5:01 PM
CORE-TIMI 72a and CORE2-TIMI 72b trials: Patients with severe hypertriglyceridemia have an increased risk of pancreatitis despite the use of lipid-lowering therapy. Research findings on the safety and efficacy of olezarsen in this population are summarized in a new video. nej.md/4bkpa7S
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | New England Journal of Medicine www.nejm.org/doi/full/10....
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | NEJM
Highly effective therapies to reduce triglyceride levels are lacking. Olezarsen is
an N-acetylgalactosamine–conjugated antisense oligonucleotide that targets the messenger
RNA of apolipoprotein C-I...
www.nejm.org
October 6, 2025 at 8:23 PM
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | New England Journal of Medicine www.nejm.org/doi/full/10....
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
July 20, 2026 at 4:45 PM
The FDA approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia. It may lower triglycerides and reduce pancreatitis risk, but it is not a blood-glucose treatment. Read: https://livingdiabetes.com/tryngolza-olezarsen-severe-hypertriglyceridemia-diabetes/ #Diabetes #HeartHealth
Essence–TIMI 73b phase 3 trial: Patients with hypertriglyceridemia have an increased risk of atherosclerosis and acute pancreatitis, but highly effective treatments to reduce triglyceride levels are lacking. Research findings are summarized in a new Quick Take video. nej.md/3VKPiQl
October 4, 2025 at 7:01 PM
Essence–TIMI 73b phase 3 trial: Patients with hypertriglyceridemia have an increased risk of atherosclerosis and acute pancreatitis, but highly effective treatments to reduce triglyceride levels are lacking. Research findings are summarized in a new Quick Take video. nej.md/3VKPiQl
Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. 🔗 More: https://bit.ly/4g4r50H
August 30, 2025 at 5:31 PM
Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. 🔗 More: https://bit.ly/4g4r50H
“Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.”
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk | NEJM
Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis.
The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein
C-III messenger R...
www.nejm.org
January 29, 2026 at 12:03 PM
“Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.”
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky #EndoSky
www.nejm.org/doi/full/10....
Compared to placebo, olezarsen dramatically reduces TG and remnant cholesterol, as we know:
April 1, 2026 at 7:14 PM
Compared to placebo, olezarsen dramatically reduces TG and remnant cholesterol, as we know:
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
cmacahilig@crf.org
Wed, 04/01/2026 - 16:06
Yael L. Maxwell
The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these patients.
www.tctmd.com
April 1, 2026 at 8:15 PM
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
Read more
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. #NEJM
www.nejm.org/doi/full/10....
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. #NEJM
www.nejm.org/doi/full/10....
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome | NEJM
Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepati...
www.nejm.org
December 20, 2024 at 12:37 AM
Read more
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. #NEJM
www.nejm.org/doi/full/10....
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. #NEJM
www.nejm.org/doi/full/10....
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Olezarsen indicated as an adjunct to diet
www.medpagetoday.com
June 24, 2026 at 8:58 PM
The FDA approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, the agency announced on Wednesday.
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
https://www.medpagetoday.com/cardiology/dyslipidemia/121914
There was no significant change in non-calcified coronary plaque volume in the olezarsen arm compared to the placebo arm.
April 1, 2026 at 7:14 PM
There was no significant change in non-calcified coronary plaque volume in the olezarsen arm compared to the placebo arm.